Glenmark Expands Ophthalmic Portfolio with Launch of Latanoprost Solution

Glenmark Pharmaceuticals Inc., USA has announced the launch of Latanoprost Ophthalmic Solution, 0.005%, expanding its prescription ophthalmic product line. This generic version of Xalatan is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The product, which achieved annual sales of approximately $111.6 million in the US market, is expected to be available through authorized distributors. Glenmark's move strengthens its position in the ophthalmic market, with the company now boasting a portfolio of 200 products authorized for distribution in the US and 51 ANDAs pending FDA approval.

 

Sources: Express Pharma, Financial Express, CNBC TV18